Laible M, et al. - RNA was extracted from tumor material derived from the estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- subjects who were receiving adjuvant endocrine treatment for low-risk cancers by the researchers in order to ask whether reverse transcription-quantitative real-time polymerase chain reaction (RT-qPCR) could be used instead to address the effect of molecular subtypes on the prediction of distant recurrence in ER+/HER2- breast cancer upon five years of endocrine therapy. Ten events in the group of 195 Luminal A-like tumors and 18 events in the remaining 127 tumors, consisting mostly of Luminal B-like cases (n=119) at a median follow up of 7.8 years, was observed. Significantly better distant disease-free survival (DDFS) in Luminal A-like over the entire follow-up period with a trend towards the decreased probability of recurrences also in the late phase was noted. In the pN0 or pN0-N1 subgroups or after correcting for clinicopathological parameters, the survival benefit spanning the entire follow-up period continued. mRNA expression of KI67 alone markedly prognosticated for worse DDFS. Hence, at ten years of follow-up, St Gallen Luminal A-like tumors recognized by RT-qPCR exhibited notably low rates of distant recurrence. Moreover, due to the obviously unfavorable benefit/toxicity ratio, subjects with such tumors could be forgiven chemotherapy.